



## **Neuren appoints Bruce Hancox to Board of Directors**

**SYDNEY, Australia, 8 March 2012:** Neuren Pharmaceuticals Limited (ASX:NEU) announced today that its Board has appointed Bruce Hancox as a director of the Company.

Mr Hancox, who has a Bachelor of Commerce degree from Canterbury University, has had a long and distinguished career in business in New Zealand and Australia. He was for many years involved with Brierley Investments Limited as General Manager, Group Chief Executive and Chairman. He also served as a director of many Brierley subsidiaries in New Zealand, Australia and the United States.

Mr Hancox became an Australian resident in 2006. Since then he has pursued various private investment interests and has been a director of and consultant to a number of companies. He has acted as advisor on a number of takeover situations. In 2007 he was appointed to the board of Australian listed company Retail Food Group Limited and became its Chairman in 2011.

Commenting on Mr Hancox's appointment, Dr Robin Congreve, Neuren's Chairman said "We are delighted that Bruce has agreed to join Neuren's board. He will be an important addition to our presence in Australia. His vast business experience will add significantly to the Board's capabilities and in particular its ability to add shareholder value when partnering and licensing opportunities become available".

Mr Hancox will also be asked to join the Company's Audit and Remuneration Committee.

### **About Neuren**

Neuren Pharmaceuticals is a biopharmaceutical company developing new therapies for brain injury, chronic neurological diseases and cancer. Neuren presently has two clinical-stage molecules, NNZ-2566 and Motiva<sup>®</sup>, in Phase II clinical trials largely funded by the US Army and the National Health and Medical Research Council, respectively. Through its subsidiary, Perseis Therapeutics Limited, Neuren is developing monoclonal antibodies against Trefoil Factors 1 and 3, proteins produced by cancer cells that are associated with cancer spread and reduced patient survival.

### **For more information, please contact:**

Larry Glass, CEO  
[lglass@neurenpharma.com](mailto:lglass@neurenpharma.com)  
Tel: +1 301 941 1830